Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rhythm Pharmaceuticals (RYTM) Net Margin (2021 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Net Margin for 5 consecutive years, with 85.3% as the latest value for Q4 2025.

  • Quarterly Net Margin rose 2140.0% to 85.3% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 106.41% through Dec 2025, up 9688.0% year-over-year, with the annual reading at 106.41% for FY2025, 9691.0% up from the prior year.
  • Net Margin for Q4 2025 was 85.3% at Rhythm Pharmaceuticals, up from 105.81% in the prior quarter.
  • The five-year high for Net Margin was 125000.0% in Q1 2021, with the low at 12915.69% in Q2 2021.
  • Average Net Margin over 5 years is 4951.49%, with a median of 184.02% recorded in 2023.
  • Peak annual rise in Net Margin hit 1242079bps in 2022, while the deepest fall reached -12850674bps in 2022.
  • Over 5 years, Net Margin stood at 2798.84% in 2021, then surged by 119bps to 527.99% in 2022, then tumbled by -133bps to 171.8% in 2023, then skyrocketed by 38bps to 106.7% in 2024, then grew by 20bps to 85.3% in 2025.
  • According to Business Quant data, Net Margin over the past three periods came in at 85.3%, 105.81%, and 98.93% for Q4 2025, Q3 2025, and Q2 2025 respectively.